Our grit drives solutions for patients. Every day, we strive to advance our pipeline of innovative medicines to treat rare diseases. By targeting the CXCR4 pathway, our novel medicines are designed to restore healthy immunity in patients with rare diseases.
Aberrant functioning of CXCR4 is associated with certain PI diseases. X4’s lead candidate, Mavorixafor, expected to initiate a Phase 3 clinical trial for the PI disease, WHIM Syndrome.
X4 is developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers, such as lymphomas.
April 12, 2019
X4 Pharmaceuticals Prices $85.8 Million Public Offering of...
April 11, 2019
X4 Pharmaceuticals Announces Proposed Public Offering of...
X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.